Regeneron Pharmaceuticals (REGN) Short-term Investments (2009 - 2026)

Regeneron Pharmaceuticals has reported Short-term Investments for 18 years, with the latest figure at $5.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Short-term Investments rose 10.11% year-over-year to $5.8 billion; the trailing twelve-month figure through Mar 2026 stood at $5.8 billion (up 10.11% YoY), and the FY2025 full-year result was $5.5 billion, down 15.9% from the prior year.
• Short-term Investments for Q1 2026 stood at $5.8 billion, up from $5.5 billion in the prior quarter.
• The five-year high for Short-term Investments was $8.1 billion in Q4 2023, with the low at $3.5 billion in Q3 2022.
• Average Short-term Investments over 5 years is $6.0 billion, with a median of $5.8 billion recorded in 2026.
• Year-over-year, Short-term Investments jumped 126.87% in 2022 and sank 33.57% in 2025.
• Tracing REGN's Short-term Investments over 5 years: stood at $4.6 billion in 2022, then surged by 75.02% to $8.1 billion in 2023, then fell by 19.6% to $6.5 billion in 2024, then dropped by 15.9% to $5.5 billion in 2025, then advanced by 5.54% to $5.8 billion in 2026.
• The last three Short-term Investments figures came in at $5.8 billion (Q1 2026), $5.5 billion (Q4 2025), and $5.9 billion (Q3 2025), per Business Quant data.

Peer Comparison